Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma
Menée initialement sur des échantillons tumoraux prélevés sur 576 patients atteints d'un adénocarcinome du poumon, puis à l'aide de techniques de séquençage à haut débit sur 24 échantillons tumoraux, cette étude met en évidence une fusion des gènes FGFR3 et TACC3 chez un petit nombre de patients, suggérant ainsi de mener des essais cliniques à l'aide d'inhibiteurs de FGFR dans cette population
Purpose: Targetable oncogenic alterations are detected more commonly in patients with non-small cell lung cancer (NSCLC) who never smoked cigarettes. For such patients, specific kinase inhibitors have emerged as effective clinical treatments. However, the currently known oncogenic alterations do not account for all never smokers who develop NSCLC. We sought to identify additional oncogenic alterations from patients with NSCLC in order to define additional treatment options. Experimental Design: We analyzed 576 lung adenocarcinomas from patients of Asian and Caucasian ethnicity. We identified a subset of cancers that did not harbor any known oncogenic alteration. We performed targeted next generation sequencing (NGS) assay on 24 patients from this set with > 75% tumor cell content. Results: EGFR mutations were the most common oncogenic alteration from both Asian (53%) and Caucasian (41.6%) patients. No known oncogenic alterations were present in 25.7% of Asian and 31% of Caucasian tumor specimens. We identified a FGFR3-TACC3 fusion event in 1 of 24 patients from this subset using targeted NGS. Two additional patients harboring FGFR3-TACC3 were identified by screening our entire cohort (overall prevalence: 0.5%). Expression of FGFR3-TACC3 led to IL-3 independent growth in Ba/F3 cells. These cells were sensitive to pan-FGFR inhibitors but not the EGFR inhibitor gefitinib. Conclusions: FGFR3-TACC3 rearrangements occur in a subset of patients with lung adenocarcinoma. Such patients should be considered for clinical trials featuring FGFR inhibitors.